Table 1.

Patient and disease characteristics

Rigosertib twice daily dosing (mg)
70140280560700Total
Patients323337a48
SexM1/F2F2M2/F1M15/F18M6/F1M24/F24
Age (range)49–7457–6351–6020–7947–7120–79
Colorectal carcinoma1010
HNSCC1326
Ovarian carcinoma224
Esophageal adenocarcinoma44
Renal cell carcinoma33
Hepatocellular carcinoma22
Breast carcinoma11a2
Uterine adenocarcinoma11
Uterine carcinosarcoma11
Leiomyosarcoma11
Cervical adenocarcinoma11
Transitional cell carcinoma11
Pancreatic neuroendocrine11
Vulvovaginal melanoma11
Carcinoid tumor11
Salivary gland carcinoma11
Gastrointestinal stromal tumor11
Craniopharyngioma11
Adrenocortical carcinoma11
SCC lung11
Osteosarcoma11
Prostate carcinoma11
SCC vulva11
Adenoid cystic nasopharyngeal11
  • aOne patient in the 700-mg cohort was taken off study for progression 2 days after starting treatment and replaced by an additional patient treated at this dose level.